Intertrochanteric Femur Fracture Patients Who Receive Metformin With a Placebo

Summary

The investigators central hypothesis is that metformin supplementation will be well-tolerated, safe, and provide patients with improved functional and muscle morphology outcomes following intertrochanteric femur fracture. The objectives will be tested in older adults that sustain a hip fracture and are randomized to receive a daily oral dose (1.5g daily) of metformin or a non-active placebo during 4 months of recovery following surgery.

Timeline

Start

2025-09-04

Primary completion

2030-09

Completion

2030-09

Drugs

Indications